about
A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinomaGreen tea consumption and stomach cancer risk: a meta-analysis.Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer.Differential impacts of insulin-like growth factor-binding protein-3 (IGFBP-3) in epithelial IGF-induced lung cancer development.Head and neck PET/CT: therapy response interpretation criteria (Hopkins Criteria)-interreader reliability, accuracy, and survival outcomesGenomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing.Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas.A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma.Chemotherapy in the treatment of metastatic gastric cancer: is there a global standard?FDG PET/CT in the management of nasopharyngeal carcinoma.Emerging biomarkers in head and neck cancer in the era of genomics.Class I HDACs are mediators of smoke carcinogen-induced stabilization of DNMT1 and serve as promising targets for chemoprevention of lung cancer.FDG PET/CT for Management and Assessing Outcomes of Squamous Cell Cancer of the Oral Cavity.Intratherapy or Posttherapy FDG PET or FDG PET/CT for Patients With Head and Neck Cancer: A Systematic Review and Meta-analysis of Prognostic Studies.Quality indicators of laryngeal cancer care in commercially insured patients.Treatment, short-term outcomes, and costs associated with larynx cancer care in commercially insured patients.SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells.Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.The role of human papillomavirus on the prognosis and treatment of oropharyngeal carcinoma.Evaluation of proposed staging systems for human papillomavirus-related oropharyngeal squamous cell carcinoma.Quality indicators of oropharyngeal cancer care in the elderly.High-resolution microbiome profiling uncovers Fusobacterium nucleatum, Lactobacillus gasseri/johnsonii, and Lactobacillus vaginalis associated to oral and oropharyngeal cancer in saliva from HPV positive and HPV negative patients treated with surgerTreatment, survival, and costs of oropharyngeal cancer care in the elderly.Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy.Whole-Exome Sequencing of Salivary Gland Mucoepidermoid Carcinoma.Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.FDG PET/CT in Patients With Head and Neck Squamous Cell Carcinoma After Primary Surgical Resection With or Without Chemoradiation Therapy.A robust response to combination immune checkpoint inhibitor therapy in HPV-related small cell cancer: a case report.Clinical Benefit to an Aurora A Kinase Inhibitor in a Patient with Metastatic Integrase Interactor 1-Deficient CarcinomaPD-1 Blockade-Induced Pruritus Treated with a Mu-Opioid Receptor AntagonistGenomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from TherapyGranulocyte colony-stimulating factor and acute myocardial infarctionAutologous bone-marrow stem cells for myocardial infarctionSystolic blood pressure and outcomes in patients hospitalized with acute heart failureTargeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket studyDetection of AR-V7 transcript with RNA in situ hybridization in human salivary duct cancerAssociation between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomasTargeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC)Pattern of planned systemic therapy usage in newly diagnosed, nonmetastatic squamous cell carcinoma of the head and neck in a commercially insured population in the United States
P50
Q27853046-71777242-8990-46A6-8396-638CE7545D0FQ33781926-5AC50D41-ED0B-442F-B196-CB4FFCA02418Q33915416-65D163A1-3B65-425F-826D-CA8CD8C9A465Q35001398-F08255DE-349D-406E-8067-6B824D94D79BQ35322315-C3D114A2-8ADF-4489-B205-03F4FFBFE117Q35892011-7A863037-C5F5-4039-8A36-95676FAD71A8Q36104229-C5EF5F8B-CA53-49E5-93A1-9BE4CB8C944FQ36447729-EF1552C5-CFBB-48A5-94B4-B84EBF41DC31Q37832986-E79E1ABF-F9D7-426D-8D22-18B82432FFB9Q38233210-39BCD2D0-49B5-479E-A257-CD467EA78F02Q38268896-3510898B-8035-4EE9-AE2B-55C9295ABA9DQ38281374-F2BE3607-46AA-45D1-9FFF-0FCDBEE88543Q38497996-46942BF0-097C-4882-BC74-5BFE91C95B60Q38615039-3684BA2F-EE76-4F0B-98A2-ABD10C59912FQ38688633-E28D0D18-EF83-49D4-AA16-9581EEAE2793Q38689797-22948B3F-A8EA-49D0-B6C5-5FC902CDA57BQ38702971-681A05A6-F9EF-4A88-89D5-B23701DA3114Q38959172-9F9D89DB-0E48-4068-BD1E-34C648E73AE0Q39193035-2D1CA355-F11D-42D4-9CCB-0ABFF3B8B7F0Q40081693-D8879E56-2D9E-4898-B84A-13E5B28ABBE3Q40384584-3AF554EF-5DAB-4D2E-B083-16AF0EB93ED0Q47305717-DC3E6EAC-AB29-4CAE-B60C-E2EB1E6D85B2Q47552742-FB9AB8A9-A610-4F8F-9846-1A0D5AA6543DQ47843407-4E52F068-4B01-4AF2-80CB-9A0EF22025C2Q47859326-04E91972-9FF8-4119-8933-0B1EF7D874C8Q50192022-E6C2DC73-E3E1-482C-A6B3-C34091B3C24DQ50317337-96903F6E-0D04-4210-8A7D-142876697FF9Q52984221-FB69C4A2-0ED6-460E-B828-33BFCB90A0BAQ55092262-BFF32B16-FB85-4BA1-93A6-960E69452316Q57295727-D90FEEFA-F867-47E8-BCCC-CA1584DA94D5Q57452473-12B95B30-36B3-4F99-B718-8852C8291EE1Q58106210-87018EA6-3A57-4BAA-9E27-CCA427918FC5Q79297765-39D0AA44-9984-4700-B2F6-282FE684CC19Q79826507-1A5CD0D7-B563-4DAF-909A-B5327F2488D2Q79843345-DDDFBF43-DB72-4482-9C29-002C5AFEE668Q89751767-29A368BC-E61F-44A9-A8CE-2F87432B6277Q91024055-D3062932-BCDB-4D46-A640-3C7B134069DAQ91252426-C55D25CF-0499-4F85-AC8F-99B29FF7B7B1Q92055924-BCB4A92A-4306-4293-AB87-E84BA620ED87Q93026818-E8FD6324-292E-475A-AC09-5DBFDED9C8D7
P50
description
researcher
@en
հետազոտող
@hy
name
Hyunseok Kang
@ast
Hyunseok Kang
@en
Hyunseok Kang
@es
Hyunseok Kang
@nl
Hyunseok Kang
@sl
type
label
Hyunseok Kang
@ast
Hyunseok Kang
@en
Hyunseok Kang
@es
Hyunseok Kang
@nl
Hyunseok Kang
@sl
prefLabel
Hyunseok Kang
@ast
Hyunseok Kang
@en
Hyunseok Kang
@es
Hyunseok Kang
@nl
Hyunseok Kang
@sl
P108
P106
P31
P496
0000-0001-5758-8202